Tiziana Life Sciences Insider Deals: CEO’s 44‑M Share Option Portfolio Signals Confidence—But Dilution Risk Lingers as 2028 Milestones Loom
Investor insights: Tiziana Life Sciences insider options reveal bullish confidence in upcoming FDA milestones, yet potential dilution and valuation risks remain.
3 minutes to read